SRCM
IBO

Signature Resources Capital Management’s Impact BioMedical IBO Stock Holding History

Signature Resources Capital Management’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$2 – 795
2025
Q4 		$2 Hold
4
– – ﹤0.01% 694
2025
Q3 		$3 Hold
4
– – ﹤0.01% 518
2025
Q2 		$3 Hold
4
– – ﹤0.01% 535
2025
Q1 		$3 Buy
+4
New +$7 ﹤0.01% 379

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Signature Resources Capital Management's IBO Position: Q1 2026 in Review

Signature Resources Capital Management sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 4 shares — an estimated $2 sold.

Signature Resources Capital Management first reported a position in IBO in Q1 2025 and held it in 4 quarters. The position peaked at $3 in Q3 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Signature Resources Capital Management reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
  • Signature Resources Capital Management sold 4 Impact BioMedical shares in Q1 2026, an estimated $2.
  • Signature Resources Capital Management first reported a position in Impact BioMedical in Q1 2025 and held it in 4 quarters.
  • Signature Resources Capital Management's Impact BioMedical position peaked at $3 in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Signature Resources Capital Management's 13F filing for Q1 2026, filed 1 May 2026.